Literature DB >> 34224184

Brain volume loss due to donanemab.

Scott Ayton1.   

Abstract

Entities:  

Keywords:  Alzheimer’s disease; Cognitive disorders and dementia; NEUROLOGICAL DISORDERS

Year:  2021        PMID： 34224184     DOI： 10.1111/ene.15007

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  4 in total

Review 1.  Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.

Authors:  Albert Garcia-Romeu; Sean Darcy; Hillary Jackson; Toni White; Paul Rosenberg
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 2.  Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer's Disease Therapeutics.

Authors:  Hyomin Jeong; Heewon Shin; Seungpyo Hong; YoungSoo Kim
Journal:  Exp Neurobiol       Date:  2022-04-30       Impact factor: 3.800

Review 3.  Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.

Authors:  Todd E Golde
Journal:  Neurotherapeutics       Date:  2022-02-28       Impact factor: 7.620

4.  Aminopeptidase A and dipeptidyl peptidase 4: a pathogenic duo in Alzheimer's disease?

Authors:  Frédéric Checler; Audrey Valverde
Journal:  Neural Regen Res       Date:  2022-10       Impact factor: 6.058
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.